Sernova Corp
XTSX:SVA
Sernova Corp
Research & Development
Sernova Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Sernova Corp
XTSX:SVA
|
Research & Development
-CA$6.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$32.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$272.7m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-34%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$14.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sernova Corp
Glance View
Sernova Corp. is a clinical stage regenerative medicine company. The company is headquartered in London, Ontario. The firm is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. The company is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device, protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. The company is also evaluating Cell Pouch for the treatment of patients with hemophilia A.
See Also
What is Sernova Corp's Research & Development?
Research & Development
-6.8m
CAD
Based on the financial report for Jan 31, 2022, Sernova Corp's Research & Development amounts to -6.8m CAD.
What is Sernova Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-48%
The average annual Research & Development growth rates for Sernova Corp have been -47% over the past three years , -48% over the past five years .